why choose us

First received: July 31, 2023

Clinical Trial: Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Study Status: Completed

Recruit Status: RECRUITING

Condition: Pancreas Neoplasm

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Dose Escalation and Expansion Study of EO-3021, an Anti-claudin 18.2 (CLDN18.2) Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Express CLDN18.2

Brief Summary: This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2.

Read more